ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Bausch + Lomb To Acquire ISTA In Cash Deal

DOW JONES NEWSWIRES Bausch + Lomb Monday agreed to acquire ISTA Pharmaceuticals Inc. (ISTA), swooping in with a higher offer for the eye-care company deal less than two months after a rival suitor withdrew its bid. ISTA shares jumped 7.8% to $9.03 after hours, slightly below Bausch + Lomb's $9.10 per-share offer price, which offers more than $380 million for Ista's outstanding shares. That values the company at a roughly 134% premium over its close Dec. 15, the day before ISTA confirmed its was weighing its strategic options. The latest offer comes after Valeant Pharmaceuticals International Inc. (VRX, VRX.T) withdrew a sweetened bid for the eye-care company. Valeant in January raised its offer for ISTA to $7.50 a share, with a target of $8.50 subject to due diligence. ISTA at the time said it would continue to review Valeant's offer, valued at up to $353 million, but said it would remain in talks with a number of parties that expressed interest in a strategic transaction. Basch + Lomb's deal, expected to close in the second quarter, won unanimous approval from both companies' boards. Basch + Lomb said the deal benefits from the two companies' complementary development pipelines. The companies plan to continue operating independently until the deal closes. -By Drew FitzGerald, Dow Jones Newswires; 212-416-2909;

Stock News for Valeant Pharma (VRX)
04/27/201621:50:00Valeant to Make Sweeping Changes to Board
04/27/201621:30:00Valeant Discloses Pay for New CEO
04/27/201620:57:00Valeant Discloses Pay for New CEO
04/27/201617:40:00Valeant Steering Away From Aggressive Price Increases, Officials...
04/27/201617:25:02Current Report Filing (8-k)
04/27/201601:20:00Valeant Was Too Aggressive in Raising Drug Prices, CEO Says
04/26/201610:20:00Former Valeant Financial Chief to Testify Before Senate
04/26/201609:58:00Former Valeant Financial Chief Schiller to Testify At Senate...
04/26/201603:04:00CEO's Departure Rattles Perrigo Shareholders -- WSJ
04/26/201603:02:00CEO Exits Show Room at Top Can Be Lonely -- WSJ
04/25/201617:23:00As Its CEO Leaves for Valeant, Perrigo Continues to Struggle...
04/25/201616:50:00As Its CEO Leaves for Valeant, Perrigo Continues to Struggle...
04/25/201614:07:00As Its CEO Leaves to for Valeant, Perrigo Continues to Struggle...
04/25/201612:43:00Valeant Names Joseph Papa as New CEO--Update
04/25/201612:17:00Perrigo Shares Tumble as CEO Leaves for Valeant, Guidance Cut...
04/25/201612:13:00Valeant Names Joseph Papa as New CEO--Update
04/25/201610:52:00Perrigo Shares Tumble as CEO Leaves for Valeant, Guidance Cut...
04/25/201610:21:00Valeant Names Joseph Papa as New CEO--Update
04/25/201609:46:00U.S. Hot Stocks: Hot Stocks to Watch
04/25/201609:41:00Valeant Names Joseph Papa as New CEO--Update

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations